Estimation of aterosclerotic cardiovascular risk in adult patients without a suspicion of having high pressure readings

Main Article Content

F.I. García-Castillo
https://orcid.org/0000-0003-3617-1592
M.Y. López-Carrillo
https://orcid.org/0000-0003-4704-760X
I.R Mendiola-Pastrana
https://orcid.org/0000-0002-5313-2432
E. López-Ortiz
https://orcid.org/0000-0002-0237-7480
D.P. Guízar-Sánchez
https://orcid.org/0000-0001-8905-6315
G. López-Ortiz
https://orcid.org/0000-0003-0280-0012

Abstract

Introduction: Cardiovascular diseases are the main cause of death in the world. The estimation of the Cardiovascular Risk (CVR) could both reduce the burden of the illness and improve the quality of life of the patients.


Objective: To estimate the CVR in adult patients without a suspicion of having high pressure readings in a Clinic of Family Medicine in Mexico City.


Methods: This is a descriptive and transversal study with a sample of 101 male and female patients in the range of 40 to 69 years old, who did not have a previous hypertension diagnosis but who, at the moment of this study, showed high tension readings. The American Heart Association 2017 criteria were used. The cardiovascular risk was assessed using the ASCVD-Risk Estimator Plus.


Results: Arterial hypertension readings were found in 55.4 % of the sample. 54.4 % of the sample met the criteria for low risk, 11.8 % for limit risk, 25.7 % for medium risk, and 7.9 % for high risk. The most prevalent factors associated with cardiovascular risk were type 2 diabetes mellitus, overweight, obesity, and hypertension.


Discussion: An important percentage of the sample showed cardiovascular risk to some degree, suggesting that perhaps using stricter parameters to define hypertension could prompt more timely interventions.


Conclusion: Considering both the high percentage of participants who demonstrated having a cardiovascular risk of concern and the high prevalence of risk factors such as Type 2 Diabetes Mellitus, hypertension, and overweight, timely monitoring interventions should be promoted in order to prevent the development of cardiovascular diseases.

Article Details

Dimensions citation

MÉTRICAS

 

References

Gómez LA. Las enfermedades cardiovasculares: un problema de salud pública y un reto global. Biomédica. 2011; 31(4): 469-73. https://bit.ly/3kk7xdB

OMS. Enfermedades cardiovasculares. Ginebra: OMS; 2017. https://bit.ly/39g7vwN

Kunstmann S, Gainza F. Herramientas para la estimación del riesgo cardiovascular. Rev. méd. Clín. Las Condes. 2018; 29(1): 6-11. https://doi.org/10.1016/j.rmclc.2017.11.010

Andrade-Castellanos CA. Hipertensión arterial primaria: tratamiento farmacológico basado en la evidencia. Med Int Méx. 2015; 31: 191-5. https://bit.ly/39lazHU

Secretaría de Salud. Guía de Práctica Clínica. Diagnóstico y tratamiento de dislipidemias (hipercolesterolemia) en el adulto. México: CENETEC; Actualización 2016. https://bit.ly/3hQl1Md

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 140(11): 596-646. https://doi.org/10.1161/CIR.0000000000000678

American Heart Association. Know your risk factors for high blood pressure. Dallas: AHA; 2020. https://bit.ly/2Xv3D8z

Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA. 2017; 317(2): 165-82. https://doi.org/10.1001/jama.2016.19043

World Health Organization. The top 10 causes of death. Ginebra: WHO; 2020. https://bit.ly/2Xtsr0K

Instituto Nacional de Salud Pública. Encuesta Nacional de Salud y Nutrición 2018. Presentación de resultados. México: INEGI/INSP/SSA; 2020. https://bit.ly/3krAy7e

Valenzuela-Flores AA, Solórzano-Santos F, Valenzuela-Flores AG, Durán-Arenas LG, Ponce de León-Rosales SP, Oropeza-Martínez MP, et al. Key recommendations of the clinical guidelines of arterial hypertension in primary care. Rev Med Inst Mex Seguro Soc. 2016; 54(2): 249-60. https://bit.ly/3u3isLN

Himmelfarb CRD, Commodore-Mensah Y, Hill MN. Expanding the role of nurses to improve hypertension care and control globally. Ann Glob Health. 2016; 82(2): 243-53. https://doi.org/10.1016/j.aogh.2016.02.003

Spies LA, Bader SG, Opollo JG, Gray J. Nurse-led interventions for hypertension: A scoping review with implications for evidence-based practice. Worldviews Evid Based Nurs. 2018; 15(4): 247-56. https://doi.org/10.1111/wvn.12297

Spies LA, Nanyonga RC, Nakaggwa F. Nurse‐led interventions in the interim: Waiting on universal health coverage. Int Nurs Rev. 2019; 66(4): 549-52. https://doi.org/10.1111/inr.12558

Taler SJ. Initial treatment of hypertension. N Engl J Med. 2018; 378(7): 636-44. https://doi.org/10.1056/NEJMcp1613481

Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71(6): 1269-324. https://doi.org/10.1161/HYP.0000000000000066

Bress AP, Colantonio LD, Cooper RS, Kramer H, Booth JN, Odden MC, et al. Potential cardiovascular disease events prevented with adoption of the 2017 American College of Cardiology/American Heart Association blood pressure guideline. Circulation. 2019; 139(1): 24-36. https://doi.org/10.1161/CIRCULATIONAHA.118.035640

Universidad Nacional Autónoma de México. Los médicos familiares, pilar de la salud. Gaceta Facultad de Medicina. 2018; 9(251): 1-16. https://bit.ly/39tq40t

León E, Tranche S, Montano J. Impacto económico de la medicina familiar en los sistemas de salud de Iberoamérica. Rev Bras Med Fam Comunidade. 2018; 13(Suppl 1): 43-53. https://doi.org/10.5712/rbmfc13(1)1852

Institute for Health Metrics and Evaluation. GBD Compare|Viz Hub. Seattle: University of Washington; 2020.

Gijón-Conde T, Gorostidi M, Camafort M, Abad-Cardiel M, Martín-Rioboo E, Morales-Olivas F, et al. Documento de la Sociedad Española de Hipertensión-Liga Española para la lucha contra la hipertensión arterial (SEH-LELHA) sobre las guías ACC/AHA 2017 de hipertensión arterial. Hipertens Riesgo Vasc. 2018; 35(3): 119-29. https://doi.org/10.1016/j.hipert.2018.04.001

Amercian College of Cardiology. ASCVD Risk Estimator Plus. Washington, D.C.: ACC; s/f. https://bit.ly/2XyIsCq

Wilson PWF, Kannel WB. Obesity, diabetes, and risk of cardiovascular disease in the elderly. Am J Geriatr Cardiol. 2002; 11(2): 119-24. https://doi.org/10.1111/j.1076-7460.2002.00998.x

Joseph JJ, Golden SH. Type 2 diabetes and cardiovascular disease: What next? Curr Opin Endocrinol Diabetes Obes. 2014; 21(2): 109-20. https://doi.org/10.1097/MED.0000000000000044

Merino J, Jablonski KA, Mercader JM, Kahn SE, Chen L, Harden M, et al. Interaction between type 2 diabetes prevention strategies and genetic determinants of coronary artery disease on cardiometabolic risk factors. Diabetes. 2020; 69(1): 112–20. https://doi.org/10.2337/db19-0097

Secretaría de Salud/Instituto Nacional de Salud Pública. Encuesta Nacional de Salud y Nutrición de Medio Camino 2016 (ENSANUT MC 2016). Informe final de resultados. México: SSA/INSP; 2016. https://bit.ly/3hW6XRo

Hinton TC, Adams ZH, Baker RP, Hope KA, Paton JFR, Hart EC, et al. Investigation and treatment of high blood pressure in young people: Too much medicine or appropriate risk reduction? Hypertension. 2020; 75(1): 16-22. https://doi.org/10.1161/HYPERTENSIONAHA.119.13820

Packer M. Heart Failure: The most important, preventable, and treatable cardiovascular complication of type 2 diabetes. Diabetes Care. 2018; 41(1): 11-3. https://doi.org/10.2337/dci17-0052

Adiukwu F, Ofori S, Ugbomah L. Vascular cognitive impairment, a cardiovascular complication. World J Psychiatry. 2016; 6(2): 199-207. https://doi.org/10.5498/wjp.v6.i2.199

Hisni D, Rukmaini R, Saryono S, Chinnawong T, Thaniwattananon P. Cardiovascular self-management support program for preventing cardiovascular complication behaviors and clinical outcomes in the elderly with poorly controlled type 2 diabetes mellitus in Indonesia: A pilot study. Jpn J Nurs Sci. 2019; 16(1): 25-36. https://doi.org/10.1111/jjns.12208

Wenger NK. Female‐friendly focus: 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease. Clin Cardiol. 2019; 42(8): 706-9. https://doi.org/10.1002/clc.23218

Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, et al. Preeclampsia and future cardiovascular health: A systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2017; 10(2): 1-9. https://doi.org/10.1161/CIRCOUTCOMES.116.003497

Woodward M. Cardiovascular disease and the female disadvantage. Int. J. Environ. Res. Public Health. 2019; 16(7): 1165.

Regitz‐Zagrosek V. Sex and gender differences in health: Science & society series on sex and science. EMBO Rep. 2012; 13(7): 596-603. https://doi.org/10.1038/embor.2012.87

Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020; 16(4): 223-37. https://doi.org/10.1038/s41581-019-0244-2

Yano Y, Reis JP, Colangelo LA, Shimbo D, Viera AJ, Allen NB, et al. Association of blood pressure classification in young adults using the 2017 American College of Cardiology/American Heart Association blood pressure Guideline with cardiovascular events later in life. JAMA. 2018; 320(17): 1774‐82. https://doi.org/10.1001/jama.2018.13551

Noubiap JJ, Bigna JJ, Nansseu JR, Nyaga UF, Balti EV, Echouffo-Tcheugui JB, et al. Prevalence of dyslipidaemia among adults in Africa: A systematic review and meta-analysis. Lancet Global Health. 2018; 6(9): e998-e1007. https://doi.org/10.1016/S2214-109X(18)30275-4

Harris MA, Ferguson TS, Boyne MS, Figueroa JP. High prevalence of dyslipidemia among primary care patients with hypertension and diabetes in Jamaica. Arch Med Sci Atheroscler Dis. 2017; 2: 61-7. https://doi.org/10.5114/amsad.2017.70596

American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of medical care in diabetes-2020. Diabetes Care. 2020; 43(Suppl. 1): S111–34. https://doi.org/10.2337/dc20-s010

Lloyd-Jones DM, Braun LT, Ndumele CE, Smith SC, Sperling LS, Virani SS, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2019; 73(24): 3153-67. https://doi.org/10.1016/j.jacc.2018.11.005

Sarre-Álvarez D, Cabrera-Jardines R, Rodríguez-Weber F, Díaz-Greene E. Enfermedad cardiovascular aterosclerótica. Revisión de las escalas de riesgo y edad cardiovascular. Med. inter Méx. 2018; 34(6): 910-23. https://bit.ly/3cZgRim

Ahuja R, Ayala C, Tong X, Wall HK, Fang J. Public awareness of health-related risks from uncontrolled hypertension. Prev Chronic Dis. 2018; 15: 1-9. https://doi.org/10.5888/pcd15.170362

Thomas C, Brennan A, Goka E, Squires HY, Brenner G, Bagguley D, et al. What are the cost-savings and health benefits of improving detection and management for six high cardiovascular risk conditions in England? An economic evaluation. BMJ Open. 2020; 10(9): 2-10. https://doi.org/10.1136/bmjopen-2020-03748

Basu S, Wagner RG, Sewpaul R, Reddy P, Davies J. Implications of scaling up cardiovascular disease treatment in South Africa: A microsimulation and cost-effectiveness analysis. Lancet Glob Health. 2019; 7(2): e270-80. https://doi.org/10.1016/S2214-109X(18)30450-9

Heintzman JD, Bailey SR, Muench J, Killerby M, Cowburn S, Marino M. Lack of lipid screening disparities in obese latino adults at health centers. Am J Prev Med. 2017; 52(6): 805-9. https://doi.org/10.1016/j.amepre.2016.12.020

Mattiuzzi C, Sanchis-Gomar F, Lippi G. Worldwide burden of LDL cholesterol: Implications in cardiovascular disease. Nutr Metab Cardiovasc Dis. 2020; 30(2): 241-4. https://doi.org/10.1016/j.numecd.2019.09.008

Escortell-Mayor E, Del Cura-González I, Ojeda-Ruiz E, Sanz-Cuesta T, Rodríguez-Salceda I, García-Soltero J, et al. A primary healthcare information intervention for communicating cardiovascular risk to patients with poorly controlled hypertension: The Education and Coronary Risk Evaluation (Educore) study-A pragmatic, cluster-randomized trial. PLoS ONE. 2020; 15(1): 1-17. https://doi.org/10.1371/journal.pone.0226398